October 2018 | DelveInsight Business Research Skip to main content
delveinsight blog
  • ABOUT
    • About Us
    • Our Leadership
    • Our Clients
  • CAPABILITIES & SOLUTIONS
    • Reports
    • Competitive Intelligence
    • Case Study
  • CONSULTING SERVICE
  • REPORT STORE
  • MEDIA
    • Blog
    • Press Releases
    • White Papers / Newsletter
    • Events
  • CAREER
  • CONTACT US
  • Report Store

Month: October 2018

Oct 31 The risk of solid cancer after chemotherapy

The risk of solid cancer after chemotherapy

Oct 31, 2018Oct 31, 2018 DelveInsight 1 Comment

Subsequent malignant neoplasms (SMNs) are one of the most serious and potentially lethal complications of cancer and its therapy. Radiotherapy has been known to be a…

Read More
Oct 30 Notizia

Notizia

Oct 30, 2018 DelveInsight Leave a comment

TherapeuticsMD bags FDA approval for hormone therapy The FDA has nodded hormone therapy of TherapeuticsMD for hot flashes that are associated with menopause. Bijuva is an…

Read More
Oct 29 Meeting the Unmet Need for Oral Mucositis

Meeting the Unmet Need for Oral Mucositis

Oct 29, 2018Oct 30, 2018 DelveInsight Leave a comment

Oral Mucositis (OM) refers to erythematous and ulcerative lesions of the oral mucosa observed in cancer patients under chemotherapy or radiation therapy. In its severe form,…

Read More
Oct 25 The Business Cocktail

The Business Cocktail

Oct 25, 2018 DelveInsight Leave a comment

Innovent Biologics reaps USD 421 Million by Hong Kong IPO Innovent Biologics got delivered USD 421 million in its IPO. The Suzhou-based unicorn priced 236.35 million…

Read More
Oct 23 Notizia

Notizia

Oct 23, 2018Oct 23, 2018 DelveInsight Leave a comment

Novartis comes up with an answer for breast cancer with PI3K drug alpelisib Novartis comes up with an answer with its recent data on BYL719 (alpelisib) in…

Read More
Oct 22 INSIGHTS ON TRIPLE NEGATIVE BREAST CANCER

INSIGHTS ON TRIPLE NEGATIVE BREAST CANCER

Oct 22, 2018Oct 23, 2018 DelveInsight 3 Comments

  To know more about TRIPLE NEGATIVE BREAST CANCER request for sample pages: https://www.delveinsight.com/dev-sample.php?form_name=Triple-Negative-Breast-Cancer-(TNBC)—Market-Insight,-Epidemiology-and-Market-Forecast-2027

Read More
Oct 18 The Business Cocktail

The Business Cocktail

Oct 18, 2018Oct 19, 2018 DelveInsight Leave a comment

Novartis signs USD 2.1Billion for Endocyte acquisition Novartis has inked USD 2.1 billion agreement to takeover Endocyte. Endocyte, a biopharmaceutical company, headquartered in Indiana, licensed the cancer drug…

Read More
Oct 17 Drugmakers will now have to reveal medicine prices in television ads

Drugmakers will now have to reveal medicine prices in television ads

Oct 17, 2018Oct 18, 2018 DelveInsight Leave a comment

Pharmaceutical companies will disclose the price of medicines in television advertisements to consumers. The step is taken up by the Trump administration to control rampant spending…

Read More
Oct 16 Notizia

Notizia

Oct 16, 2018Oct 17, 2018 DelveInsight Leave a comment

FDA approves expanded label for Xarelto of Johnson & Johnson The Food and Drug Administration permitted labelling of blood thinner, Xarelto of Johnson & Johnson, as…

Read More
Oct 12 Is Gene Therapy the Next Cancer Treatment Revolution? 

Is Gene Therapy the Next Cancer Treatment Revolution? 

Oct 12, 2018 DelveInsight 4 Comments

Gene Therapy is now touted as a new revolution for cancer treatment. If the list of new cancer treatment methodologies is traversed, then the end seems…

Read More

Posts navigation

1 2 3 Older posts

Recent Posts

  • Acquisition of ArQule; Synthorx; and Zentalis nabs a raise
  • Are Rare diseases truly Rare?
  • Hype over Gene Therapy: Challenges and Opportunities
  • Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval
  • The Regulatory process for drug approval in the MENA region

Browse by Category

  • Anti-coagulants (8)
  • API Business Opportunity (5)
  • Articles (284)
  • Atrial Fibrillation (6)
  • Business Consultant (446)
    • Pharma Consultant (427)
  • Chimeric Antigen Receptor (CAR) T-cell Therapy (7)
  • CNS Indications (1)
  • CVS Indications (4)
  • DelveInsight's Drug Report (154)
  • DelveInsight's Indication Pipeline Reports (68)
  • DelveInsight's Oncology based Reports (46)
  • Gene Therapy Products (31)
  • Infographics (40)
  • new therapeutic target (5)
  • Newsletter (2)
  • Notizia (155)
  • Oncology based Indications (11)
  • Orphan market (4)
  • PD-1 and PD-L1 inhibitors (5)
  • Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors (1)
  • Pulmonary arterial hypertension (1)
  • Rising of Orphan Drug Development (3)
  • Snippets (127)
  • Specialized Reports (15)
  • The Business Cocktail (139)
  • Uncategorized (61)
  • Venous Thromboembolism (3)

Archives

  • December 2019 (9)
  • November 2019 (24)
  • October 2019 (27)
  • September 2019 (23)
  • August 2019 (22)
  • July 2019 (25)
  • June 2019 (30)
  • May 2019 (29)
  • April 2019 (29)
  • March 2019 (27)
  • February 2019 (20)
  • January 2019 (18)
  • December 2018 (19)
  • November 2018 (26)
  • October 2018 (21)
  • September 2018 (20)
  • August 2018 (26)
  • July 2018 (13)
  • June 2018 (5)
  • May 2018 (8)
  • April 2018 (6)
  • March 2018 (14)
  • February 2018 (11)
  • January 2018 (15)
  • December 2017 (8)
  • November 2017 (13)
  • October 2017 (8)
  • September 2017 (14)
  • August 2017 (13)
  • July 2017 (9)
  • June 2017 (14)
  • May 2017 (20)
  • April 2017 (19)
  • March 2017 (24)
  • February 2017 (21)
  • January 2017 (23)
  • December 2016 (22)
  • November 2016 (23)
  • October 2016 (17)
  • September 2016 (21)
  • August 2016 (17)
  • May 2016 (4)
  • March 2016 (8)
  • February 2016 (3)
  • January 2016 (7)
  • November 2015 (1)
  • October 2015 (1)
  • September 2015 (2)
  • August 2015 (2)
  • July 2015 (8)
  • June 2015 (4)
  • May 2015 (1)
  • April 2015 (5)
  • March 2015 (6)
  • February 2015 (2)
  • January 2015 (5)
  • December 2014 (17)
  • November 2014 (2)
  • September 2014 (1)
  • August 2014 (7)
  • July 2014 (7)
delveinsight


Quick Links

  • About
  • Capabilities & Solutions
  • Report Store
  • Media
  • Career
  • Contact Us

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Tweets by @DelveInsight

Copyright © 2019 Delveinsight.

  • Sitemap
  • Terms & Conditions
  • Privacy policy